Appointment strengthens board independence and financial expertise as Company advances its clinical pipeline.
BEVERLY HILLS, California, September 2, 2026 (GLOBE NEWSWIRE) — Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a biotech company specializing in developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders, announced today the appointment of Elizabeth Addonizio as an independent member of its Board of Directors (the “Board”), effective September 1, 2026.
Elizabeth Addonizio is a finance professional with 25 years of business and leadership experience in venture and private equity investing and investment banking. She has spent the past decade investing with families and entrepreneurs in U.S.-based, sector-agnostic early-stage companies and has also served as a fractional CFO across diverse sectors. Previously, she was a managing director at Cranemere, where she evaluated middle-market private equity investments, served on the Investment Committee, and led diligence, financing, and acquisition activities. Earlier, she worked at Morgan Stanley advising on more than $25 billion in M&A, leveraged finance, and equity transactions. In addition to her work in finance, since 2004, Ms. Addonizio has served as an officer in the U.S. Navy Reserve. Currently, she is the board-selected Commanding Officer of the 30-member Navy Reserve Office of Naval Intelligence (ONI) Kennedy Maritime Analysis Center Unit in St. Louis, MO. During her twenty-plus years in the U.S. Navy, she has led numerous teams in support of U.S. European Command, ONI, Naval Criminal Investigative Service (NCIS), and the Defense Intelligence Agency (DIA). She also served 20 months of active military duty as an analyst on the personal staff of the then Commander of U.S. Central Command, General David Petraeus.
“We are very pleased to welcome Elizabeth to our Board,” said Henrik Rouf, President and Chief Executive Officer of Nordicus. “Elizabeth brings a rare combination of institutional investment banking experience, private equity and venture investing discipline, and hands-on CFO and board-level work with early-stage companies. As we advance QR-01 and QR-02 toward clinical trials and continue to pursue our uplisting to a major national exchange, her financial expertise and governance experience will be an important asset to our shareholders.”
“Nordicus has assembled a differentiated portfolio of Nordic-originated assets addressing conditions with significant unmet medical need and no approved treatments,” said Ms. Addonizio. “I look forward to working with Henrik and the Board to help build the financial and governance foundation required to support the Company’s next stage of growth, including access to institutional capital.”
About Nordicus Partners Corporation:
Nordicus Partners Corporation is a U.S. based biotech company focusing on acquiring and developing drugs from innovative biotech companies in the Nordics, a region known for its brilliant scientists, exceptional life science ecosystem and drug discoveries and developments. Nordicus is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs – starting with oral disorders. Its scientific foundation targets inflammation and immune modulation. In 2024, Nordicus acquired 100% of Orocidin A/S, a Danish preclinical-stage biotech company developing next-generation therapies for periodontitis and 100% of Bio-Convert A/S, a Danish preclinical-stage biotech company dedicated to revolutionizing the treatment of oral leukoplakia. For more information about Nordicus, please visit: www.nordicuspartners.com, and follow us on LinkedIn and X
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue,” “confident” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition, prospects of being listed on Nasdaq, studies related to Orocidin, Bio-Convert and NoviThera and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For further information, contact:
Nordicus Partners
Mr. Henrik Rouf
Chief Executive Officer
hr@nordicuspartners.com
Tel +1 310 666 0750
Hayden IR
Brett Maas
(646) 536-7331
James Carbonara
(646)-755-7412
Kim T. Mücke is a Danish state authorized public accountant (authorization deposited in 2025). He was partner with Deloitte (Denmark) in the period 2002 to 2022 where he – among others – served as signing partner for various listed companies including companies that underwent IPO processes. In the years 2023-2024, Mr. Mücke was Head of Corporate Clients for BDO (Denmark). From 1 January 2025, Mr. Mücke has started as independent advisor,specialized in financial reporting, risk management and corporate governance. Mr. Mücke has a master’s degree in Auditing and Accounting from the Copenhagen Business School.
Elizabeth Addonizio is an experienced finance professional with twenty-five years of business and leadership experience. She is the founder of Fair Winds Capital LLC, AMN LLC, and GEDI LLC, through which she has spent the past decade investing, along with families and entrepreneurs, in U.S.-based, sector-agnostic, early-stage venture investments that prioritize impact and environmental, social, and good governance (ESG) principles by investing in companies’ Pre-seed to C-round capital raises. She has also served as a fractional CFO for many companies in diverse sectors.
Prior to her venture investing and CFO work, from 2012 to 2016, Ms. Addonizio was a founding managing director and investment professional at Cranemere, an international investment holding company and private equity firm structured to invest with a commitment to sustainability and ESG principles, along with other families, in middle market private companies (~$200mm-$500mm in enterprise value). While at Cranemere she sourced and evaluated dozens of investment opportunities, serving on the firm’s Investment Committee, and overseeing due diligence, financing, and other acquisition-related activities. Prior to joining Cranemere, from 2006 to 2012, Ms. Addonizio worked at Morgan Stanley in the Investment Banking and Corporate M&A and Strategy Divisions, advising on over $25 billion of mergers and acquisitions, leveraged finance, and equity transactions.
In addition to her work in finance, since 2004, Ms. Addonizio has served as an intelligence officer in the U.S. Navy Reserve. Currently, she is the board-selected Commanding Officer of the 30-member Navy Reserve Office of Naval Intelligence (ONI) Kennedy Maritime Analysis Center Unit in St. Louis, MO. Previously, she was Executive Officer of 110+-person Navy Reserve Joint Intelligence Operations Center Europe (JIOCEUR) Analytic Center Molesworth 0366 (located at Joint Reserve Intelligence Support Element Sheridan, Fort Sheridan, IL). Prior to this position, she served as the board-selected Executive Officer of 75-person ONI Navy Reserve Nimitz Unit at Fort Dix, NJ. She was also the Officer in Charge (OIC) of a twenty-eight-person Naval Criminal Investigative Service (NCIS) Unit based in New London, CT. Board-selected to hold this position, she was one of only three to have command of a unit at her rank in the Navy Reserve Intelligence Community, the first woman to ever serve in this NCIS unit, and by extension, the unit’s first female OIC. During her twenty years in the U.S. Navy, she has led numerous teams in support of JIOCEUR, ONI, NCIS, and the Defense Intelligence Agency (DIA). She also served 20 months of active military duty as an analyst on the personal staff of the Commander of U.S. Central Command, General David Petraeus.
Earlier in her career, Ms. Addonizio was elected to serve two terms as the 9th Ward Alderwoman in New Haven, Connecticut, serving as the Vice Chair of the Finance Committee with legislative oversight of the city’s $450 million annual budget. As a Henry Luce Scholar in China, she taught economics at Peking University and worked on China’s accession to the World Trade Organization at the World Bank Resident Mission. She has also worked in the U.S. National Security Council and in the Office of the U.S. Trade Representative. She holds a Ph.D. from Yale University, a M.P.A. from Princeton University, a B.A. from Bucknell University, and was a Fulbright Scholar in El Salvador. Ms. Addonizio is currently a member of the Association for Corporate Growth and the Alliance of Merger and Acquisitions Advisers. She is also a Council on Foreign Relations Life Member, a NationSwell Council Member, a Truman National Security Project Fellow, and a Yale World Fellow.